CTOs on the Move

Particle Sciences Inc

www.particlesciences.com

 
Particle Sciences Inc is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Prevention Point Philadelphia

Prevention Point Philadelphia is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

361md

361md - a leading healthcare IT Company, represents a complete 360 degree solution for hospitals, doctors' offices, expert physicians, diagnostic labs, pharmacies, health insurance companies and other healthcare providers including nursing homes and rehab facilities.

Sinai Residences

Sinai Residences is a retirement community in Boca Raton that offers luxurious surroundings and a culture of sophistication. They provide top-notch independent and assisted living, memory care, rehab, and skilled nursing services on site.

Rally Health

Rally® believes in putting health care in the hands of individuals with a seamless experience, providing personalized, data-driven information and recommendations that can help improve outcomes and decrease costs for everyone. Rallys Health Solutions help members set personalized daily goals, gives recommendations, and incentivizes progress with rewards. Rallys Care Solutions make health benefits easy to understand and care easy to find on the computer or the Rally app. More than 20 million consumers currently have access to the Rally platform through payers such as UnitedHealthcare, BlueCross BlueShield of South Carolina, and thousands of employer groups. Across offices in Washington, D.C., San Francisco, Chicago, Minneapolis, Denver, and Las Vegas, Rallyers have dedicated themselves to transforming the health care industry for the better—Together.

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company`s pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert`s proven intravitreal drug delivery platform has been safely administered to thousands of patients` eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.